JPMorgan raised Bruker’s price target by 44% citing growth in microbiology diagnostics and new FDA-approved system updates.
JPMorgan analyst Casey Woodring increased Bruker Corporation’s (NASDAQ:BRKR) price target to $65 from $45 while maintaining an Overweight rating. The adjustment follows updates to the company’s financial model and recent advancements in its diagnostics portfolio.
Bruker recently showcased its expanding microbiology and infection diagnostics tools at ASM Microbe 2026, including FDA-approved updates to its MALDI Biotyper CA System. The system now identifies 549 clinically validated microbial species, with software upgrades aimed at improving lab efficiency. The firm also introduced research-use tools covering 5,325 species.
The company is developing a rapid antimicrobial susceptibility testing workflow to enable faster clinical decisions for critically ill patients. Bruker serves biotechnology, pharmaceutical, and life sciences markets with diagnostic instruments and tests.